Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
GMP-PDBH19 | Human | GMP Human PDGF-BB Protein | ![]() |
![]() ![]() |
|
PDB-H4112 | Human | Human PDGF-BB Protein, premium grade | ![]() |
![]() ![]() |
|
PDB-H5127 | Human | Unconjugated Human PDGF-BB Protein, His,Avitag™ | ![]() |
![]() ![]() |
GMP Human PDGF-BB Protein (Cat. No. GMP-PDBH19) stimulates proliferation of NIH/3T3 cells. The specific activity of GMP Human PDGF-BB Protein is >5.00 x 10^5 IU/mg, which is calibrated against human PDGF-BB WHO International Standard (NIBSC code: 94/728) (QC tested).
Human PDGF-BB, premium grade (Cat. No. PDB-H4112) stimulates proliferation of NIH/3T3 cells. The specific activity of Human PDGF-BB, premium grade is >5.00 x 10^5 IU/mg, which is calibrated against human PDGF-BB WHO International Standard (NIBSC code: 94/728) (QC tested).
Immobilized Unconjugated Human PDGF-BB, His,Avitag (Cat. No. PDB-H5127) at 1 μg/mL (100 μL/well) can bind Human PDGF R beta, Fc Tag (Cat. No. PDB-H5259) with a linear range of 0.5-16 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Asengeprast | SHP-627; FT-011; FT-11; FT-001 | Phase 2 Clinical | Fibrotech Therapeutics Pty Ltd, University Of Melbourne | Scleroderma, Systemic; Scleroderma, Diffuse; Retinal Degeneration | Details |
Recombinant Human Platelet-derived Growth Factor B(Lynch Regenerative Medicine) | rhPDGF-BB | Phase 2 Clinical | Lynch Regenerative Medicine LLC | Rectal Fistula | Details |
HL-217 | HL-217; KR-31831 | Phase 1 Clinical | Korea Research Institute Of Chemical Technology | Macular Degeneration | Details |
REGN-13335 | REGN13335; REGN-13335 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Details |
This web search service is supported by Google Inc.